Omeros: No Partner - No Money

|
About: Omeros Corporation (OMER), Includes: ALXN
by: Mehdi Mehdiyev
This article is exclusive for subscribers.
Mehdi Mehdiyev
Long/short equity, Deep Value, value, Growth
Summary

Even with Medicare support, Omidria sales performance is not encouraging.

If approved, the lead candidate can face competition in a crowded market.

Absence of a commercial partner brings the risk of dilution.

Omeros Corporation (NASDAQ:OMER) is commercial stage pharmaceutical company with one marketed drug - Omidria, one late-stage, and several early-stage drug candidates.

Omidria is used during cataract surgery or intraocular lens replacement and is